Jing Ning
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jing Ning has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- Suyu Liu
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, TX
1 shared publication
Latest Publications
- Open Access
- 1 September 2013
- Published by Institute of Mathematical Statistics in Bayesian Analysis
- Vol. 8 (3) , 703-722
A Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities
We propose a Bayesian adaptive dose-finding design for drug combination trials with delayed toxicity. We model the dose-toxicity relationship using the Finney model, a model widely used in drug-drug interaction studies. The intuitive interpretations of the Finney model facilitate incorporating the available prior dose-toxicity information from single-agent trials into combination trials through prior elicitation. We treat unobserved delayed toxicity outcomes as missing data and handle them using Bayesian data augmentation. We conduct extensive simulation studies to examine the operating characteristics of the proposed method under various practical scenarios. Results show that the proposed design is safe and able to select the target dose combinations with high probabilities.
- 1 September 2013
- Published by Institute of Mathematical Statistics in Bayesian Analysis
- Vol. 8 (3) , 703-722
Open AccessA Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities
We propose a Bayesian adaptive dose-finding design for drug combination trials with delayed toxicity. We model the dose-toxicity relationship using the Finney model, a model widely used in drug-drug interaction studies. The intuitive interpretations of the Finney model facilitate incorporating the available prior dose-toxicity information from single-agent trials into combination trials through prior elicitation. We treat unobserved delayed toxicity outcomes as missing data and handle them using Bayesian data augmentation. We conduct extensive simulation studies to examine the operating characteristics of the proposed method under various practical scenarios. Results show that the proposed design is safe and able to select the target dose combinations with high probabilities.